drugset / Trial / NCT03232632

Assessment of Cardiac Fixation During PET Using a New Drug Within Amyloid Cardiac Injuries.

NCT03232632

Phase 0 Terminated 7 enrolled University Hospital, Toulouse
NaSingle-groupOpen-labelSupportive care

Summary

To estimate distribution's parameters of 18F-Flutemetamol (Vizamyl®) fixation on myocardium for patients with amyloid cardiac injuries.

Timeline

Start
2017-03-15
Primary completion
2019-09-15
Completion
2019-09-15

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-Flutemetamol Diagnostic / imaging agent

Indications